Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

8.720 +0.050 (+0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 321,206
Open 8.620
Bid (Size) 8.500 (2)
Ask (Size) 8.990 (1)
Prev. Close 8.670
Today's Range 8.620 - 8.980
52wk Range 6.510 - 11.49
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
7 Small-Cap Stocks Analysts Predict Will Double in 2024
While small-cap stocks to buy present exceptional risk, they also offer tremendous rewards for intrepid retail investors. 
Via InvestorPlace

Performance

YTD
+11.37%
+11.37%
1 Month
-10.38%
-10.38%
3 Month
+20.44%
+20.44%
6 Month
+3.07%
+3.07%
1 Year
+3.32%
+3.32%

More News

Read More
Evolus to Participate in September Conferences
From Evolus
Via Business Wire
Evolus Announces Inducement Grants for New Chief Marketing Officer
From Evolus
Via Business Wire
Earnings Preview: Evolus
Via Benzinga
5 Analysts Have This to Say About Evolus
Via Benzinga
Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action
Via Investor Brand Network
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
From Evolus
Via Business Wire
Over $15M Bet On Impinj? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Via Newsfile
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
From Evolus
Via Business Wire
Why Shares of Evolus Are Jumping Thursday
Via The Motley Fool
Expert Ratings for Evolus
Via Benzinga
This Analyst Likes Evolus As 'Top Play In Aesthetics'
Via Benzinga
Evolus Reports Second Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Comcast, STMicroelectronics, Lam Research, Meta Platforms And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
From Evolus, Inc.
Via Business Wire
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
Twitter Faces Threats From AI and Threads
Via The Motley Fool
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.